Every claim on Luscious Locs rests on published studies of individual ingredients — same ingredient, same form, and, where we say so, the same dose. The finished formula has not been trialled and is never described as clinically proven or clinically backed.
Supplier- or maker-funded trials are disclosed next to the ingredient they support. This page does not link out; sources are cited here by author and year.
Cynatine® HNS is keratin in peptide form. It has been studied in a randomized, controlled trial at this 500 mg dose for hair strength, shine, and appearance (Beer, 2014). That trial was supplier-funded (Roxlor), which we disclose here.
Ashwagandha is included for everyday stress support.* A well-known published trial of KSM-66® used 600 mg (Chandrasekhar, 2012). Our daily amount is 300 mg — half that dose — and that difference is disclosed here. We do not attach that trial’s outcomes to this 300 mg amount.
AnaGain™ Nu has been studied at this 100 mg dose in a published pilot (Grothe, 2020). Researchers reported changes in hair appearance over a 28-day period. The study was open-label and included authors affiliated with the ingredient maker, which we disclose here.
Lustriva® has been studied at this 160 mg dose in a randomized, controlled trial of 90 women (Kalman & Hewlings, 2021). Researchers reported changes in hair appearance in the early weeks of the trial. The study was maker-funded, which we disclose here. The 160 mg serving also supplies the silicon and biotin in this formula.
In an eight-month randomized, controlled trial, participants taking 100 mg of tocotrienols had a 34.5% increase in hair count, compared with essentially no change (−0.1%) in the placebo group (Beoy, 2010). A 2023 systematic review in JAMA Dermatology, covering 30 studies, rated the tocotrienol evidence as good quality. These findings apply to the ingredient, not to the finished Luscious Locs formula.
L-cysteine is the rate-limiting amino acid in keratin production and is included as a building block of hair’s structural protein.* Supporting literature is drawn from nutritional and combination-formula research, not from a standalone hair-endpoint trial of this 100 mg amount.
Iron status is one of the most studied nutritional factors related to women’s hair (Trost, 2006, Journal of the American Academy of Dermatology). We use Ferrochel®, a bisglycinate chelate, at 18 mg. This product contains iron; please read the iron warning in the footer.
Zinc is included as a core mineral for hair and skin, in a chelated bisglycinate form, at a standard supplemental amount.*
Vitamin D3 is included as a foundational nutrient. Low vitamin D status has been discussed in published case-control literature relating to women’s hair. This is a nutritional inclusion, not a treatment claim.
Vitamin C is included to support collagen synthesis and the absorption of the iron in this formula.*
Folate is included as a core nutrient involved in cell division, at a standard dietary amount.*
Vitamin B12 is included at a nutritional level, not as a megadose.*
Selenium is included at a standard nutritional amount as part of the mineral foundation of the formula.*
Silicon, provided through Lustriva®, has been studied for its relationship to hair tensile strength (Wickett, 2007). There is no separate silicon line item beyond what Lustriva® supplies.
Biotin is not added as a standalone megadose. A published review has noted that biotin supplementation is most clearly helpful when a deficiency is present (Patel, 2017). Biotin may interfere with laboratory tests. Tell your healthcare provider you take this product if you are having lab work.
Independent and academic anchors we rely on include Beoy, 2010 (tocotrienols); Trost, 2006 (iron status and women’s hair); a 2017 micronutrient review (Thompson); Patel, 2017 (biotin); and a 2023 systematic review in JAMA Dermatology. Supplier-funded trials — including Beer, 2014 for Cynatine®, Kalman & Hewlings, 2021 for Lustriva®, and Grothe, 2020 for AnaGain™ — are listed with that context.
None of this is evidence for the finished bottle as a whole. If a dose is described as “full studied dose,” it was chosen to match the amount used in the cited study. If it differs, we say so.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Planning doses are targets for formulator and regulatory confirmation.